Remission maintenance treatment options in chronic lymphocytic leukemia.

Alexander Egle; Lisa Pleyer; Thomas Melchardt; Tanja Hartmann; Richard Greil

doi:10.1016/j.ctrv.2018.08.003

Remission maintenance treatment options in chronic lymphocytic leukemia.

Alexander Egle (First author), Lisa Pleyer (Co-author), Thomas Melchardt (Co-author), Tanja Hartmann (Co-author), Richard Greil^* (Last author)

^*Corresponding author for this work

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Review article › peer-review

2 Citations (Web of Science)

Original language	English
Pages (from-to)	56-66
Journal	CANCER TREATMENT REVIEWS
Volume	70
DOIs	https://doi.org/10.1016/j.ctrv.2018.08.003
Publication status	Published - 2018

Keywords

MINIMAL RESIDUAL DISEASE
PROGRESSION-FREE SURVIVAL
PHASE-II TRIAL
FLUDARABINE-CYCLOPHOSPHAMIDE-RITUXIMAB
MULTIPARAMETER FLOW-CYTOMETRY
TERM-FOLLOW-UP
CLONAL EVOLUTION
OPEN-LABEL
ALEMTUZUMAB CONSOLIDATION
1ST-LINE TREATMENT

Access to Document

10.1016/j.ctrv.2018.08.003

Cite this

Egle, A., Pleyer, L., Melchardt, T., Hartmann, T., & Greil, R. (2018). Remission maintenance treatment options in chronic lymphocytic leukemia. CANCER TREATMENT REVIEWS , 70, 56-66. https://doi.org/10.1016/j.ctrv.2018.08.003

Egle, Alexander ; Pleyer, Lisa ; Melchardt, Thomas et al. / Remission maintenance treatment options in chronic lymphocytic leukemia. In: CANCER TREATMENT REVIEWS 2018 ; Vol. 70. pp. 56-66.

@article{b07693fe7b85477f8a8e221ce7c1057a,

title = "Remission maintenance treatment options in chronic lymphocytic leukemia.",

keywords = "MINIMAL RESIDUAL DISEASE, PROGRESSION-FREE SURVIVAL, PHASE-II TRIAL, FLUDARABINE-CYCLOPHOSPHAMIDE-RITUXIMAB, MULTIPARAMETER FLOW-CYTOMETRY, TERM-FOLLOW-UP, CLONAL EVOLUTION, OPEN-LABEL, ALEMTUZUMAB CONSOLIDATION, 1ST-LINE TREATMENT",

author = "Alexander Egle and Lisa Pleyer and Thomas Melchardt and Tanja Hartmann and Richard Greil",

note = "Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Austria; Salzburg Cancer Research Institute and Cancer Cluster Salzburg, Austria",

year = "2018",

doi = "10.1016/j.ctrv.2018.08.003",

language = "English",

volume = "70",

pages = "56--66",

journal = "CANCER TREATMENT REVIEWS ",

issn = "0305-7372",

}

Egle, A , Pleyer, L , Melchardt, T, Hartmann, T & Greil, R 2018, 'Remission maintenance treatment options in chronic lymphocytic leukemia.', CANCER TREATMENT REVIEWS , vol. 70, pp. 56-66. https://doi.org/10.1016/j.ctrv.2018.08.003

Remission maintenance treatment options in chronic lymphocytic leukemia. / Egle, Alexander (First author); Pleyer, Lisa (Co-author); Melchardt, Thomas (Co-author) et al.
In: CANCER TREATMENT REVIEWS , Vol. 70, 2018, p. 56-66.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - Remission maintenance treatment options in chronic lymphocytic leukemia.

AU - Egle, Alexander

AU - Pleyer, Lisa

AU - Melchardt, Thomas

AU - Hartmann, Tanja

AU - Greil, Richard

N1 - Department of Internal Medicine III with Hematology, Medical Oncology, Hemostaseology, Infectious Disease, Rheumatology, Oncologic Center, Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University Salzburg, Austria; Salzburg Cancer Research Institute and Cancer Cluster Salzburg, Austria

PY - 2018

Y1 - 2018

KW - MINIMAL RESIDUAL DISEASE

KW - PROGRESSION-FREE SURVIVAL

KW - PHASE-II TRIAL

KW - FLUDARABINE-CYCLOPHOSPHAMIDE-RITUXIMAB

KW - MULTIPARAMETER FLOW-CYTOMETRY

KW - TERM-FOLLOW-UP

KW - CLONAL EVOLUTION

KW - OPEN-LABEL

KW - ALEMTUZUMAB CONSOLIDATION

KW - 1ST-LINE TREATMENT

U2 - 10.1016/j.ctrv.2018.08.003

DO - 10.1016/j.ctrv.2018.08.003

M3 - Review article

C2 - 30121491

SN - 0305-7372

VL - 70

SP - 56

EP - 66

JO - CANCER TREATMENT REVIEWS

JF - CANCER TREATMENT REVIEWS

ER -

Egle A , Pleyer L , Melchardt T, Hartmann T, Greil R. Remission maintenance treatment options in chronic lymphocytic leukemia. CANCER TREATMENT REVIEWS . 2018;70:56-66. doi: 10.1016/j.ctrv.2018.08.003